Akademik Veri Yönetim Sistemi
Scientific Reports, cilt.15, sa.1, 2025 (SCI-Expanded)
It was aimed to investigate the frequency of metabolic dysfunction–associated steatotic liver disease (MASLD) in type 2 diabetes mellitus (T2DM) patients with non-invasive tests. We prospectively evaluated the frequency of MASLD and fibrosis stage of the liver with biomarkers based on blood tests and FibroScan® in adult patients with T2DM who were followed up from the outpatient clinic in a tertiary center. Liver stiffness measurement (LSM) ≥ 8 kPa was accepted as clinically significant fibrosis (≥ F2), and ≥ 12 kPa was accepted as advanced fibrosis (F3-4) in FibroScan® measurements. The cut-off value of the CAP score was accepted as 275 dB/m for steatosis. There were 504 patients with T2DM in the study. 54.2% were female. 252 (50%) patients had MASLD. 30.6% had clinically significant fibrosis, and 13.5% had advanced fibrosis. The degree of steatosis in the patients increased, the frequency of clinically significant fibrosis increased (p < 0.05). The frequency of MASLD significantly increased as BMI increased (p < 0.05). Diabetic nephropathy and neuropathy were more common in MASLD patients (p < 0.05). There was a significant relationship between clinically significant fibrosis and nephropathy (p < 0.001). MASLD and significant liver fibrosis are highly common in patients with T2DM. As the severity of liver steatosis increases, fibrosis stage progresses.